Allogene (ALLO) stock jumped 41% on promising ALPHA3 trial data showing 58% MRD clearance with no CAR T toxicities. Baird ups target to $9.

It identified automated transaction bots, synthetic identity creation, deep fake impersonation, and AI-generated shell ...

Market resilience amid Hormuz shutdown: Gareth Soloway on S&P V-bottoms, oil & gas, semiconductor warning, MRVL spike, ...

PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III ...

When your team's manager makes an on-field decision, what he’s essentially doing is calculating likely outcomes – ...

Solid Power stock is a "Hold" as a speculative pre-commercial energy-tech bet. Click to learn more about SLDP's valuation and ...

Jaguar has undergone one of the biggest resets in automotive history. These are the models to look for if you're not ...

CLEVELAND, Ohio — A Subtext subscriber asked the Wine and Gold Talk podcast crew a question they couldn’t ignore. “If the ...

In my latest book, Uplifting Leadership, I emphasise the importance of forging a visionary consensus to generate performance ...

Market strategist Gareth Soloway dissects oil's impact on equities, S&P 500 targets, Russell 2000 risks, de-dollarization, ...

Compare the best Ontario online blackjack sites for 2026. Learn expert blackjack strategies, rules, game variation and see ...

Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.